GSK’s Nucala improves control of severe asthma
GlaxoSmithKline has presented data showing that its biologic Nucala improved asthma control in patients with severe disease not adequately managed with Novartis’ Xolair.
Read More
Tag: OSMO
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
- Taiwan Bio partners with Terumo to advance automated Treg manufacturing
- Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis
- Lebrikizumab shows strong results for children with atopic dermatitis
- MHRA approves new treatment for severe alopecia areata
